Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug - Hims & Hers had partnered with ...

Kristian Tuxen Ladegaard Berg / SOPA Images / LightRocket via Getty Images U.S.-listed shares of Novo Nordisk fell more than 5% Monday after the Ozempic and Wegovy maker released results for its ...

Hims & Hers stock has fallen nearly 30% on Monday after Novo Nordisk announced it is ending its collaboration with the telehealth company, saying they sell knock-off ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 29.2% in the morning session after Novo Nordisk, the maker ...

Novo Nordisk (NVO) and Hims and Hers Health (HIMS) shares are sinking on an ended partnership, with the former also ...

However, the relationship soured quickly as Novo Nordisk discovered that “Hims & Hers Health, Inc. has failed to adhere to ...

Novo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...

Hims & Hers Health Inc.’s stock fell sharply on Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug ...

Novo Nordisk ends partnership with Hims & Hers over safety and marketing concerns tied to compounded Wegovy, as rivalry with ...

Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

Hims stock took a major hit after Novo Nordisk suddenly ended their Wegovy partnership, causing shares to drop over 20% in a single day. The breakup came after Novo raised concerns about Hims selling ...